Comparative Pharmacology
Head-to-head clinical analysis: QDOLO versus TAPENTADOL HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: QDOLO versus TAPENTADOL HYDROCHLORIDE.
QDOLO vs TAPENTADOL HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tramadol is a centrally acting synthetic opioid analgesic. It binds to μ-opioid receptors and inhibits norepinephrine and serotonin reuptake.
Tapentadol is a centrally-acting synthetic analgesic with a dual mechanism of action: mu-opioid receptor agonism and norepinephrine reuptake inhibition. It has no significant activity at other opioid receptors and minimal serotonergic effects.
Oral: 50-100 mg every 4-6 hours as needed for pain; maximum 400 mg per day. Immediate-release tablets only. Extended-release formulations require different dosing and are not interchangeable.
Adults: Immediate-release tablets: 50-100 mg orally every 4-6 hours as needed for pain, not to exceed 600 mg per day. Extended-release tablets: 50 mg orally twice daily, titrated to a maximum of 500 mg per day.
None Documented
None Documented
Terminal elimination half-life approximately 2-4 hours in adults; prolonged to 4-6 hours in elderly and up to 12-16 hours in severe renal impairment (CrCl <30 mL/min)
4 hours (terminal elimination half-life, clinically relevant for dosing interval every 4-6 hours; prolonged in moderate-severe hepatic impairment [up to 6.4 hours] and moderate-severe renal impairment [up to 7.5 hours]).
Renal 90% (60% unchanged, 30% as glucuronide conjugate), fecal 10%
Primarily renal (95% excreted in urine; 30% as unchanged tapentadol, 55% as tapentadol-O-glucuronide, and 10% as minor metabolites). Fecal elimination accounts for <3%.
Category C
Category A/B
Opioid Agonist
Opioid Agonist